Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Public ClinicalTrials.gov record NCT02316834. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
POSITION: A Pilot Study of Induction PARP Inhibition in Ovarian Cancer
Study identification
- NCT ID
- NCT02316834
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 4 participants
Conditions and interventions
Conditions
- Fallopian Tube Serous Adenocarcinoma
- High Grade Ovarian Serous Adenocarcinoma
- Ovarian Mass
- Primary Peritoneal Serous Adenocarcinoma
- Stage III Fallopian Tube Cancer AJCC v7
- Stage III Ovarian Cancer AJCC v6 and v7
- Stage III Primary Peritoneal Cancer AJCC v7
- Stage IIIA Fallopian Tube Cancer AJCC v7
- Stage IIIA Ovarian Cancer AJCC v6 and v7
- Stage IIIA Primary Peritoneal Cancer AJCC v7
- Stage IIIB Fallopian Tube Cancer AJCC v7
- Stage IIIB Ovarian Cancer AJCC v6 and v7
- Stage IIIB Primary Peritoneal Cancer AJCC v7
- Stage IIIC Fallopian Tube Cancer AJCC v7
- Stage IIIC Ovarian Cancer AJCC v6 and v7
- Stage IIIC Primary Peritoneal Cancer AJCC v7
- Stage IV Fallopian Tube Cancer AJCC v6 and v7
- Stage IV Ovarian Cancer AJCC v6 and v7
- Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
- BMN 673 Drug
- Laboratory Biomarker Analysis Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 1, 2015
- Primary completion
- Jan 13, 2022
- Completion
- Jan 13, 2022
- Last update posted
- Feb 23, 2022
2015 – 2022
United States locations
- U.S. sites
- 6
- U.S. states
- 1
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| The Woman's Hospital of Texas | Houston | Texas | 77054 | — |
| MD Anderson Regional Care Center-Katy | Houston | Texas | 77094 | — |
| MD Anderson Regional Care Center-Bay Area | Nassau Bay | Texas | 77058 | — |
| MD Anderson Regional Care Center-Sugar Land | Sugar Land | Texas | 77478 | — |
| MD Anderson Regional Care Center-The Woodlands | The Woodlands | Texas | 77384 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02316834, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2022 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02316834 live on ClinicalTrials.gov.